Timothy J. Scannell Sells 4,666 Shares of Stryker Co. (NYSE:SYK) Stock

Share on StockTwits

Stryker Co. (NYSE:SYK) COO Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $217.08, for a total value of $1,012,895.28. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of SYK opened at $219.02 on Thursday. The firm has a market capitalization of $82.32 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 2.63 and a beta of 0.85. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.26 and a current ratio of 2.07. Stryker Co. has a one year low of $144.75 and a one year high of $222.59. The stock’s fifty day moving average is $212.01 and its 200-day moving average is $195.73.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The company had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. During the same period last year, the company earned $1.76 earnings per share. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Analysts forecast that Stryker Co. will post 8.21 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.08 annualized dividend and a yield of 0.95%. Stryker’s dividend payout ratio is currently 28.45%.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Stryker by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock valued at $5,496,241,000 after purchasing an additional 555,327 shares during the period. BlackRock Inc. boosted its position in shares of Stryker by 0.6% in the 1st quarter. BlackRock Inc. now owns 25,036,303 shares of the medical technology company’s stock valued at $4,945,168,000 after purchasing an additional 153,391 shares during the period. FMR LLC boosted its position in shares of Stryker by 13.4% in the 1st quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock valued at $1,328,951,000 after purchasing an additional 793,560 shares during the period. Fundsmith LLP boosted its position in shares of Stryker by 1.0% in the 1st quarter. Fundsmith LLP now owns 5,581,841 shares of the medical technology company’s stock valued at $1,102,525,000 after purchasing an additional 52,688 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Stryker by 0.5% in the 2nd quarter. Northern Trust Corp now owns 3,922,830 shares of the medical technology company’s stock valued at $806,455,000 after purchasing an additional 19,248 shares during the period. 74.14% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have weighed in on the company. Morgan Stanley increased their target price on Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. Barclays set a $226.00 target price on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Royal Bank of Canada set a $220.00 target price on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Credit Suisse Group increased their target price on Stryker from $232.00 to $237.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Finally, Cantor Fitzgerald increased their target price on Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a research report on Friday, July 26th. Five research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Why Dividend Stocks May Be Right for You

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
Line Corp  Shares Sold by CSat Investment Advisory L.P.
Line Corp Shares Sold by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report